We further observed that tumor malignancy was significantly lower in patients with mutations in the DNA-binding domain of STAT3 compared to those with the mutations in the SH2 domain (χ2=12.346, p=0.011) and the N- or C-terminal regions (χ2=5.611, p=0.027) (Figure 1A). This evidence concerns the gene STAT3 and neoplasm.